IDH2 and central nervous system cancer: Results from ongoing trials testing the DNA methyltransferase inhibitors decitabine and 5-azacytidine in recurrent IDH-mutant gliomas (NCT03922555 and NCT03666559, respectively) will be helpful in this regard.